摘要
目的对比分析两种不同质子泵抑制剂联合促胃动力药治疗反流性食管炎的疗效及安全性影响。方法选取2018年2月1日~2020年2月1日接受治疗的反流性食管炎患者90例,按数字奇偶法将其分为观察组与对照组(各45例),两组入院后均临床接受常规治疗,对照组在常规治疗基础上接受奥美拉唑+莫沙必利治疗,观察组在常规治疗基础上接受埃索美拉唑+伊托必利治疗,连续治疗8周后,观察记录两组临床症状改善时间,并评估其临床疗效及不良反应。结果治疗后,观察组临床症状(胸痛、反酸、烧心、吞咽困难)改善时间显著早于对照组(P<0.05);观察组临床治疗总有效率(93.33%)显著高于对照组(68.89%)(P<0.05);观察组腹痛、腹泻、失眠等不良反应总发生率(8.88%)明显低于对照组(15.55%)(P>0.05)。结论与奥美拉唑联合莫沙必利比较,埃索美拉唑联合伊托必利治疗反流性食管炎更能明显改善患者临床症状,提高临床疗效,且不良反应轻。
Objective To compare the efficacy and safety of two different proton pump inhibitors combined with gastric prokinetic drugs in the treatment of reflux esophagitis.Methods 90 patients with reflux esophagitis who were treated in our hospital from February 1,2018 to February 1,2020 were selected and divided into the observation group and the control group(45 cases in each group)according to the digital parity method.Both groups received conventional treatment after admission.The control group received omeprazole+mosapride treatment basis on conventional treatment,and the observation group received esomeprazole+itopride treatment basis on conventional treatment.After 8 weeks of treatment,the improvement time of clinical symptoms was observed and recorded,and the clinical efficacy and adverse reactions were evaluated.Results After treatment,the improvement time of clinical symptoms(chest pain,acid regurgitation,heartburn,dysphagia)in the combination group was significantly earlier than that in the control group(P<0.05);the total effective rate of the combined group(93.33%)was significantly higher than that of the control group(68.89%)(P<0.05);The total incidence of abdominal pain,diarrhea,insomnia and other adverse reactions in the observation group(8.88%)was significantly lower than that in the control group(15.55%)(P>0.05).Conclusion Compared with omeprazole combined with mosapride,esomeprazole combined with itopride can significantly improve the clinical symptoms and clinical efficacy of patients with reflux esophagitis,and the adverse reactions are mild.
作者
张立伟
ZHANG Li-wei(Department of Digestive Medicine,Xinxian People's Hospital,Liaocheng 252400,China)
出处
《中国处方药》
2021年第4期55-56,共2页
Journal of China Prescription Drug
